Gastroenterology published a ‘special issue’ in January 2018 (volume 154; pages 263-451) which reviewed several esophageal diseases in-depth: gastroesophageal reflux disease (GERD), eosinophilic esophagitis (EoE), and esophageal cancer. For me, this issue served as a good review on GERD and EoE.
A couple of items that I picked up:
- For both GERD and functional dyspepsia, “estimated prevalence values are approximately 20% for each.” (pg 269)
- “15% of healthy individuals may have microscopic esophagitis” (pg 291)
- For pH-impedance, the current view of non-acid reflux is unchanged: “unknown clinical relevance of non-acid reflux in the setting of aggressive acid suppression.” (pg 291)
- Treatment algorithm for EoE (pg 353):
- Induction treatment with any of the three approaches: high dose topical corticosteroids, double dose proton pump inhibitor (PPI) or elimination diet “because no comparative studies have shown any of these to be superior to the others.”
- Then, re-evaluation after 2-3 months (clinical, endoscopic, and histologic). Responders should continue on therapy but maintenance treatment suggests low dose topical corticosteroid, lowering PPI to single dose, or continuing elimination diet. For nonresponders, switching to one of the other two treatment approaches is recommended.
- The algorithm indicates that followup evaluation of responders to insure ongoing response should be considered 1 year later
- As for dilatation, the authors note that this does not control the underlying inflammation and thus should not be used as monotherapy. Also, “after dilatation, 75% of patients have considerable chest pain that may last several days.” (pg 354)
Unrelated twitter post below -IgG allergy testing is NOT a good idea: